Apyx Medical Corporation

Apyx Medical Corporation

2.65
USD
-0.16
(-5.69%)
-0.19EPS
103.20MMarket Cap
Mar 18Next Earn

Total Valuation

USD

As of September 30, 2026, Apyx Medical Corporation carries a market capitalization of 103.20M, placing it among publicly traded companies globally. Its enterprise value stands at 117.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap103.20M
Enterprise Value117.58M

Important Dates

Apyx Medical Corporation's next confirmed earnings release is scheduled for March 18, 2027.

Earnings Date3/18/2027

Share Statistics

As of September 30, 2026, Apyx Medical Corporation has 42.12M shares outstanding.

Shares Outstanding42.12M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 10.72.

PS Ratio1.79
PB Ratio10.72
P/TBV Ratio10.72
P/FCF Ratio-11.97
P/OCF Ratio-12.94

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 117.58M versus a market cap of 103.20M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.97

Financial Position

As of September 30, 2026, Apyx Medical Corporation maintains a current ratio of 4.95, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 395.99, indicating elevated leverage, while an interest coverage ratio of -0.44 demonstrates limited ability to service its debt obligations.

Current Ratio4.95
Quick Ratio3.74
Debt / Equity395.99
Debt / EBITDA-16.08
Interest Coverage-0.44

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Apyx Medical Corporation posted a negative return on equity (ROE) of -108.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.17, reflecting losses generated across the asset base. The company generates approximately 290,575.61 in revenue per employee across its workforce of 205.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.06 indicates how many times Apyx Medical Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-108.99
Return on Assets (ROA)-14.17
Revenue Per Employee290,575.61
Employee Count205.00
Inventory Turnover2.06

Taxes

USD

Over the twelve months ended September 30, 2026, Apyx Medical Corporation recorded 477,000.00 in income tax expense. The company reported a pretax loss of -7.78M and -8.43M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax477,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Apyx Medical Corporation's stock has declined approximately 32.05% over the past 52 weeks. The 50-day moving average sits at 2.72, while the 200-day moving average is 3.54.

52-Week Price Change-32.05%
50-Day Moving Average2.72
200-Day Moving Average3.54

Income Statement

USD

Over the twelve months ended September 30, 2026, Apyx Medical Corporation generated 59.57M in revenue and converted that into -8.43M in net income, yielding earnings per share of -0.19. EBITDA reached -2.47M, while operating income came in at -3.28M.

Revenue59.57M
Gross Profit37.80M
Operating Income-3.28M
Pretax Income-7.78M
Net Income-8.43M
EBITDA-2.47M
EBIT-3.28M
Earnings Per Share (EPS)-0.19

Balance Sheet

USD

As of September 30, 2026, Apyx Medical Corporation holds 25.78M in cash and equivalents against 39.75M in total debt, resulting in a net debt position of 9.80M. Total book value stands at 9.63M, with working capital of 42.97M providing operational flexibility.

Cash & Cash Equivalents25.78M
Total Debt39.75M
Net Debt9.80M
Equity (Book Value)9.63M
Book Value Per Share0.23
Working Capital42.97M

Cash Flow

USD

Apyx Medical Corporation produced -8.23M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -666,000.00 in capital expenditures, free cash flow totaled -8.89M - equivalent to -0.20 per share.

Operating Cash Flow-8.23M
Capital Expenditures-666,000.00
Free Cash Flow-8.89M
FCF Per Share-0.20

Margins

Over the twelve months ended September 30, 2026, Apyx Medical Corporation posted a gross margin of 63.45, reflecting its pricing power and cost economics. The operating margin of -5.50 and net profit margin of -14.16 provide insight into operational efficiency.

Gross Margin63.45
Operating Margin-5.50
Pretax Margin-13.07
Profit Margin-14.16
EBITDA Margin-4.15

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -8.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.26, meaning Apyx Medical Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-9.26
FCF Yield-8.35

Stock Splits

Apyx Medical Corporation's most recent stock split took place on January 6, 1994 with a 15:1 split ratio.

Last Split Date1/6/1994
Split Ratio15:1

Scores

As of September 30, 2026, Apyx Medical Corporation has an Altman Z-Score of 0.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.64